Rocket Pharmaceuticals Inc [NASDAQ: RCKT] loss -19.62% on the last trading session, reaching $6.31 price per share at the time.
If compared to the average trading volume of 2.43M shares, RCKT reached a trading volume of 5895224 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Rocket Pharmaceuticals Inc [RCKT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RCKT shares is $39.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RCKT stock is a recommendation set at 1.12. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BMO Capital Markets have made an estimate for Rocket Pharmaceuticals Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 12, 2025. While these analysts kept the previous recommendation, Wedbush raised their target price to Outperform. The new note on the price target was released on December 30, 2024, representing the official price target for Rocket Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $29, while Jefferies analysts kept a Buy rating on RCKT stock.
The Average True Range (ATR) for Rocket Pharmaceuticals Inc is set at 0.63 The Price to Book ratio for the last quarter was 1.45, with the Price to Cash per share for the same quarter was set at 3.49.
Trading performance analysis for RCKT stock
Rocket Pharmaceuticals Inc [RCKT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.32. With this latest performance, RCKT shares gained by 23.24% in over the last four-week period, additionally sinking by -62.10% over the last 6 months – not to mention a drop of -72.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RCKT stock in for the last two-week period is set at 42.01, with the RSI for the last a single of trading hit 38.23, and the three-weeks RSI is set at 42.57 for Rocket Pharmaceuticals Inc [RCKT]. The present Moving Average for the last 50 days of trading for this stock 7.51, while it was recorded at 7.53 for the last single week of trading, and 13.74 for the last 200 days.
Rocket Pharmaceuticals Inc [RCKT]: A deeper dive into fundamental analysis
Rocket Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.30 and a Current Ratio set at 9.30.
Rocket Pharmaceuticals Inc [RCKT]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RCKT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Rocket Pharmaceuticals Inc go to 60.19%.
An analysis of Institutional ownership at Rocket Pharmaceuticals Inc [RCKT]
The top three institutional holders of RCKT stocks are: RTW INVESTMENTS, LP with ownership of 17.69 million shares, which is approximately 18.8677%. WELLINGTON MANAGEMENT GROUP LLP, holding 9.16 million shares of the stock with an approximate value of $$197.12 million in RCKT stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $$133.33 million in RCKT stock with ownership which is approximately 6.6057%.
